Cargando…

Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer

Pre-operative discrimination of malignant masses is crucial for accurate diagnosis and prompt referral to a gynae oncology centre for optimal surgical intervention. HGSOC progression is correlated with local and systemic inflammation. We hypothesised that inclusion of inflammatory biomarkers in sera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kampan, Nirmala Chandralega, Madondo, Mutsa Tatenda, Reynolds, John, Hallo, Julene, McNally, Orla M., Jobling, Thomas W., Stephens, Andrew N., Quinn, Michael A., Plebanski, Magdalena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010756/ https://www.ncbi.nlm.nih.gov/pubmed/32042020 http://dx.doi.org/10.1038/s41598-020-59009-z

Ejemplares similares

Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2017)

Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2015)

Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2023)

Mapping Epitopes Recognised by Autoantibodies Shows Potential for the Diagnosis of High-Grade Serous Ovarian Cancer and Monitoring Response to Therapy for This Malignancy
por: Moody, Rhiane, et al.
Publicado: (2021)

Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression
por: Gao, Qian, et al.
Publicado: (2018)

Prognostic Value of TNFR2 and STAT3 among High-Grade Serous Ovarian Cancer Survivors According to Platinum Sensitivity
por: Silva Raju, Janisha, et al.
Publicado: (2021)

Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations
por: Madondo, Mutsa T, et al.
Publicado: (2014)

Where are we going with sentinel nodes mapping in ovarian cancer?
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2022)

Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

New Predictive Biomarkers for Ovarian Cancer
por: Atallah, Ghofraan Abdulsalam, et al.
Publicado: (2021)

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system
por: Bound, Nirashaa T., et al.
Publicado: (2022)

Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer
por: Lokman, Noor A., et al.
Publicado: (2021)

Substantially Modified Ratios of Effector to Regulatory T Cells During Chemotherapy in Ovarian Cancer Patients Return to Pre-Treatment Levels at Completion: Implications for Immunotherapy
por: Park, Anthony, et al.
Publicado: (2012)

Fatal cardiac tamponade following cytoreductive surgery for serous carcinoma of the ovary
por: English, Emily, et al.
Publicado: (2015)

Successful External Cephalic Version: Factors Predicting Vaginal Birth
por: Lim, Pei Shan, et al.
Publicado: (2014)

A Review of Placenta and Umbilical Cord-Derived Stem Cells and the Immunomodulatory Basis of Their Therapeutic Potential in Bronchopulmonary Dysplasia
por: Chia, Wai Kit, et al.
Publicado: (2021)

Keratin-14 (KRT14) Positive Leader Cells Mediate Mesothelial Clearance and Invasion by Ovarian Cancer Cells
por: Bilandzic, Maree, et al.
Publicado: (2019)

Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer
por: Kang, Sung-Woog, et al.
Publicado: (2021)

Sexual Dysfunction among Gynaecological Cancer Survivors: A Descriptive Cross-Sectional Study in Malaysia
por: Mohamad Muhit, Akmal Muzamir, et al.
Publicado: (2022)

Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers
por: Atallah, Ghofraan Abdulsalam, et al.
Publicado: (2023)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Concurrent Primary Peritoneal Low-Grade Serous Carcinoma and Endometrial High-Grade Serous Carcinoma
por: Lockyer, Megan G., et al.
Publicado: (2015)

Investigation of Interleukin-27 in the Sera of Nonmelanoma Skin Cancer Patients
por: Ghahartars, Mehdi, et al.
Publicado: (2018)

Analysis of Interleukin-17, Interleukin-23, neopterin and Nesfatin-1 levels in the sera of Hashimoto patients
por: Bayraktar, Nihayet, et al.
Publicado: (2023)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Chemoresistance is mediated by ovarian cancer leader cells in vitro
por: Karimnia, Nazanin, et al.
Publicado: (2021)

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models
por: Ho, Gwo Yaw, et al.
Publicado: (2023)

Bilateral Serous Psammocarcinoma of Ovary: Rare Variant Low Grade Serous Carcinoma
por: Jena, Saubhagya Kumar, et al.
Publicado: (2015)

The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma
por: Stronach, Euan A., et al.
Publicado: (2015)

Pelvic floor muscle training delivered via telehealth to treat urinary and/or faecal incontinence after gynaecological cancer surgery: a single cohort feasibility study
por: Brennen, Robyn, et al.
Publicado: (2023)

Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

The Continuum of Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary
por: Wong, Kwong-Kwok, et al.
Publicado: (2007)

Oncogenes in high grade serous adenocarcinoma of the ovary
por: Manasa, Pacharla, et al.
Publicado: (2020)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
por: Ribeiro e Ribeiro, Renan, et al.
Publicado: (2021)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Perception and knowledge of human papillomavirus (HPV) vaccine for cervical cancer prevention among fully vaccinated female university students in the era of HPV vaccination: a cross-sectional study
por: Chew, Kah Teik, et al.
Publicado: (2021)

CT features of low grade serous carcinoma of the ovary
por: Pannu, Harpreet K.
Publicado: (2015)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qaim8f3vd4bjdp4dlf9adbdr7r